NCT06565975View on ClinicalTrials.gov

Characteristics and Outcomes of Acute Myeloid Leukemia (AML) Patients Treated With Oral-Azacitidine Maintenance Therapy in France

Active, not recruitingOBSERVATIONAL
Enrollment

112

Participants

Timeline

Start Date

May 23, 2023

Primary Completion Date

October 31, 2024

Study Completion Date

October 31, 2024

Conditions
Acute Myeloid Leukemia (AML)
Interventions
DRUG

Oral azacitidine

As per product label, prescribed by treating physician

Trial Locations (1)

75002

Kappa Sante, Paris

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT06565975 - Characteristics and Outcomes of Acute Myeloid Leukemia (AML) Patients Treated With Oral-Azacitidine Maintenance Therapy in France | Biotech Hunter | Biotech Hunter